Clinical Considerations with Glaucoma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases -
Carding Or Hand-Stripping?
Should Your Dog be Carded or Hand-Stripped? Many K9 guardians must groom their own dogs because of the coronavirus shutdown. So EquiGroomer wants to help make your grooming smarter, not harder! For example, does your canine need carding or hand-stripping? If you are like many dog owners, you are suddenly finding yourself faced with grooming your dog while many grooming businesses remain on lockdown as non-essential businesses. With the arrival of spring and even summer temperatures, many are challenged with effectively grooming their dog’s undercoat and topcoat after the long winter. With more daylight hours and warmer temperatures, shedding dogs are a big issue right now. So, does your dog need carding, hand-stripping, both or neither one? (Hint: they are not the same thing.) Before you decide, we will take a quick look at each process separately. The Dog’s Undercoat: Carding Carding is a grooming term - and process - to describe the removal of a dog’s undercoat. The undercoat is the soft, short, downy and dense hair under the top (or outer) coat. The undercoat insulates and protects the skin in colder weather. Carding is accomplished by using: • A fine-toothed blade; • A stripping knife; • An undercoat rake; or • Another shedding tool like the gentle EquiGroomer’s Shedding Blades (pictured below). The shedding tool will grab, pull and remove (or thin out) the dead or molted undercoat hair which may not fall out on its own with the warmer temperatures. Removing this heavier winter undercoat will also help your canine stay comfortable - and cooler – in the heat. -
Sometimes God Picks the Prettiest Flowers
Sometimes God Picks the Prettiest Flowers Eulogy to Ch. Gaelforce Postscript "Peggy Sue" By Dr. Vandra L. Huber©i I'm afraid misfortune of devastating proportions has hit our house. On June 26, 1996 Am. Can. Ch. Gaelforce Postscript " Peggy Sue" (She went BIS at the Westminster Kennel club in 1995) was diagnosed with liver cancer. She has been close to death all week. At 4 a.m. July 3, 1996 she died in her puppy bed. She was 5 1/2 years. We buried her in our garden next to my foundation bitch, Am. Can. Ch. Maggie McMuffin V. She had her favorite carrot toy, some dog biscuits. I found a Scottie garden statue and placed it on top of her grave to stand watch. We planted some lovely Scotch Moss and Forget-me knots. We still are uncertain what type of cancer it was. We believe that it was lymphosarcoma which attacks dogs between 5 and 7 years of age and is more common in Scotties than many breeds. This form of cancer is usual treatable and life can be extended for 6 months to three years. But it didn't happen with Peggy. Her cancer was concentrated in her liver, one of the worse and most unusual places for cancer in canines. I am fortunate that the only board certified oncologist in Washington State, Karria A. Meleo, worked five miles from my house. So I feel my beloved Peggy Sue was getting the best of the care. My primary veterinarian Susan Torganson was also there for me. -
Fluid Ophthalmic Composition Based on Lipid Microparticles Containing at Least One Active Principle
Europaisches Patentamt J European Patent Office Office europden des brevets (11) Publication number : 0 437 368 A1 EUROPEAN PATENT APPLICATION (21) Application number: 91300181.4 ® int. ci.5 : A61K 9/06, A61K 9/16 @ Date of filing : 10.01.91 © Priority : 12.01.90 FR 9000340 (72) Inventor : Rozier, Annouk 23 Bd Lafayette F-63000 Clermont-Ferrand (FR) @ Date of publication of application : 17.07.91 Bulletin 91/29 74) Representative : Hesketh, Alan, Dr. et al European Patent Department Merck & Co., @ Designated Contracting States : Inc. Tertings Park Eastwick Road CH DE FR GB IT LI NL Harlow Essex, CM20 2QR (GB) © Applicant : LABORATOIRES MERCK, SHARP & DOHME-CHIBRET 3, Avenue Hoche F-75008 Paris (FR) (S) Fluid ophthalmic composition based on lipid microparticles containing at least one active principle. (57) There is described a fluid ophthalmic composition which comprises a suspension in a fluid dispersant medium of lipid microparticles containing at least one active principle. The composition enables improved availability of the active principle to be obtained as a result of high intraocular levels. 00 <0 CO Q. UJ Jouve, 18, rue Saint-Denis, 75001 PARIS EP 0 437 368 A1 FLUID OPHTHALMIC COMPOSITION BASED ON LIPID MICROPARTICLES CONTAINING AT LEAST ONE ACTIVE PRINCIPLE The present invention relates to a fluid ophthalmic composition. Many ophthalmic compositions are currently available in liquid or solid form, but none of them is, in fact, completely satisfactory. In effect, liquid ophthalmic compositions, although easy to use, have some drawbacks ; in particular, it is 5 difficult to obtain a sustained or delayed action of the active principle which they contain. -
NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (Apraclonidine Hydrochloride) Eye Drops 0.5%
NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (apraclonidine hydrochloride) Eye Drops 0.5%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of Iopidine Eye Drops 0.5% contains apraclonidine hydrochloride 5.75 mg, equivalent to apraclonidine base 5 mg. Excipient with known effect Benzalkonium chloride 0.1 mg per 1 mL as a preservative. For the full list of excipients, see section 6.1. 2. PHARMACEUTICAL FORM Eye drops, solution, sterile, isotonic. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Iopidine Eye Drops 0.5% are indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with Iopidine Eye Drops 0.5% to delay surgery should have frequent follow up examinations and treatment should be discontinued if the intraocular pressure rises significantly. The addition of Iopidine Eye Drops 0.5% to patients already using two aqueous suppressing drugs (i.e. beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine is an aqueous-suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP-lowering efficacy of Iopidine Eye Drops 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month. 4.2. Dose and method of administration Dose One drop of Iopidine Eye Drops 0.5% should be instilled into the affected eye(s) three times per day. -
Top Terrier of the Year BC All Terrier Club: Canadian Top Dog Points (Breed + Group Placements and BIS), Owned by a BC All Terrier Club Member
Top Terrier of the Year BC All Terrier Club: Canadian Top Dog Points (breed + group placements and BIS), owned by a BC All Terrier Club member Year Breed Dog Name Owner 2011 Welsh Terrier Am GCh & Can Ch. Darwyn's I'm Not Arguing That Larisa Hotchin 2010 Welsh Terrier Am & Can Ch. Darwyn's Webslinger Larisa Hotchin 2009 Norwich Terrier Ch. Amblegreen Spoiled Not Rotten Cyndy Monk & Heather Tomlins 2008 Miniature Schnauzer Ch. Envoy Foxy III BS Jack Daniels Holly BenYosef 2007 Lakeland Terrier Am & Can Ch. Waterwalk Stella Artois Judy Gruzelier 2006 Scottish Terrier Am & Can Ch. Beinnein's Crinan of Argyll Heather & David Lindberg 2005 Scottish Terrier Ch. Glenfraser's Morgan Devil Barry Truax & Denis Blais 2004 Miniature Schnauzer Am & Can Ch. Annfield Touch N Go Don Emslie & Tim Doxtater 2003 Miniature Schnauzer Am & Can Ch. Annfield Touch N Go Don Emslie & Tim Doxtater 2002 Miniature Schnauzer Am & Can Ch. Annfield Touch N Go Don Emslie & Tim Doxtater 2001 Miniature Schnauzer Am & Can Ch. Annfield Oh For Sure Don Emslie & Tim Doxtater 2000 Miniature Schnauzer Am & Can Ch. Annfield Oh For Sure Don Emslie & Tim Doxtater 1999 Miniature Schnauzer Am & Can Ch. Annfield Oh For Sure Don Emslie & Tim Doxtater 1998 Miniature Schnauzer Am & Can Ch. Annfield Oh For Sure Don Emslie & Tim Doxtater 1997 Miniature Schnauzer Am & Can Ch. Annfield Very Much in Touch Don Emslie & Tim Doxtater 1996 Miniature Schnauzer Am & Can Ch. Annfield Very Much in Touch Don Emslie & Tim Doxtater 1995 Irish Terrier Ch. Fairplay's Raging Cajun Cheryle Goodfellow 1994 Irish Terrier Ch. -
Printing File Backup.Pub
Rules for Non-Pet Owners Who Visit and then Complain About Our Pets 1. The pets live here. You don't. 2. If you don't want their hair on your clothes, stay off the furniture. (That's why it's called “fur"niture.) TERRIER TIMES 3. To you, our pets are just animals. To us, they are an adopted son/daughter who happens to be hairy, walks on all fours and doesn't speak clearly. February 2006 4. Yes, he has some disgusting habits. So do I, and so do you. What's your point? 5. OF COURSE he smells like a dog. 6. It's his nature to try to sniff your crotch. Please feel free to sniff his. 7. Don't be upset if the dog lifts his leg on your trousers, they probably smell like his favourite lamppost. 8. I like him a lot better than I like most people. 9. Dogs and cats are better than kids because: - they don't ask for money all the time - they are easier to train - they usually come when called - they don't hang out with drug-using friends - they don't need a gazillion rand for a varsity education, and - if they get pregnant, you can sell the children. ☺ Pass this on to other pet-lovers in your life! ☺ BREEDS REPRESENTED BY THE CAPE TERRIER CLUB: Airedale, American Staffordshire, Bedlington, Border, Bull, Cairn, Dandie Dinmont, Fox (Smooth and Wire), Irish, Jack Russell, Kerry Blue, Lakeland, Norfolk, Norwich, Parson Russell, Scottish, Skye, Sealyham, Soft-Coated Wheaten, Staffordshire Bull, Welsh & West Highland White Terriers. -
WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/066834 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 25 October 2013 (25.10.201 3) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/719,144 26 October 2012 (26. 10.2012) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: FORSIGHT VISION5, INC. [US/US]; 191 kind of regional protection available): ARIPO (BW, GH, Jefferson Drive, Menlo Park, CA 94025 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: RUBIN, Anne, Brody; 191 Jefferson Drive, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Menlo Park, CA 94025 (US). -
NEW CONCEPTS in GLAUCOMA CARE TREATMENT Proceedings of the Fifteenth Annual Meeting & of the Optometric Glaucoma Society
NEW CONCEPTS IN GLAUCOMA CARE TREATMENT Proceedings of the Fifteenth Annual Meeting & of the Optometric Glaucoma Society INSIDE: • Virtual Reality Uses in Glaucoma • Questions Glaucoma Patients Ask • Pathogenesis of Glaucoma • Glaucoma Progression • Real-Time Aqueous Humor Outfl ow Imaginging APRIL 2017 REVIEW OF OPTOMETRY/APRIL 2017 1 0217_OGS_ja_3.22.indd 1 3/24/17 3:36 PM ro0417ogs_vyzulta.indd 1 3/20/17 1:57 PM NEW CONCEPTS IN GLAUCOMA CARE TREATMENT TABLE OF CONTENTS INTRODUCTORY REMARKS The 15th Annual Scientifi c Meeting of the Optometric Glaucoma Society (OGS), held Nov. 15 and 16, 2016, in Anaheim, Calif., brought 3 together some of the country’s top luminaries INTRODUCTORY REMARKS in the areas of glaucoma diagnosis, treatment, Highlights From the Annual Scientifi c assessment, and management. These individu- Meeting als shared groundbreaking research and the BY MURRAY FINGERET, OD latest clinical knowledge about glaucoma—con- sidered to be the top global eye burden by the World Health Organization. 4 Kicking things off in the President’s Lecture, PRESIDENT’S LECTURE Felipe A. Medeiros, MD, PhD, highlighted potential clinical applications for More Than a Video Game: Virtual virtual reality devices. These devices, being tested in simulation laboratories, Reality and Its Uses in Glaucoma could one day assist clinicians in assessing patients at risk for glaucoma and BY FELIPE A. MEDEIROS, MD, PHD in danger of falls and motor vehicle accidents due to visual fi eld loss. Make no mistake: These cutting-edge tools are not your techie’s virtual reality. Dr. Medeiros, in a separate lecture about glaucoma progression, unveiled 6 an innovative metric developed by his research group to measure functional PATIENT CARE and structural vision loss in glaucoma patients. -
Efficacy and Safety of the Fixed Combinations of Tafluprost/Timolol
www.nature.com/scientificreports OPEN Efcacy and safety of the fxed combinations of tafuprost/timolol and latanoprost/carteolol Received: 4 February 2019 Masahiro Fuwa, Atsushi Shimazaki, Masafumi Mieda, Naoko Yamashita, Takahiro Akaishi, Accepted: 7 May 2019 Takazumi Taniguchi & Masatomo Kato Published: xx xx xxxx In this study, we made a comparative efcacy and safety assessment of two diferent fxed combinations of drugs, viz., tafuprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their efects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic efects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more efective in lowering IOP for a longer duration compared to LAT/CAR. We found that the diference in the intensity of IOP-lowering efect was because of the diferences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafuprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic efects compared to LAT/CAR on the human corneal epithelial cells. Our fndings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering efect in monkeys and toxicity on ocular surface. Glaucoma is a neurodegenerative disease of the eyes characterised by selective retinal ganglion cell loss, fol- lowed by progressive defects in visual feld, resulting in the principal cause of irreversible blindness worldwide1–4. Elevated intraocular pressure (IOP) is an important contributor for the progression of glaucoma, for which the current treatment primarily involves IOP reduction1,5–8. -
DOG BREEDS Affenpinscher Afghan Hound Airedale Terrier Akita
DOG BREEDS English Foxhound Polish Lowland English Setter Sheepdog Affenpinscher English Springer Pomeranian Afghan Hound Spaniel Poodle Airedale Terrier English Toy Spaniel Portuguese Water Dog Akita Field Spaniel Pug Alaskan Malamute Finnish Spitz Puli American Eskimo Dog Flat-Coated Retriever Rhodesian Ridgeback American Foxhound French Bulldog Rottweiler American Staffordshire German Pinscher Saint Bernard Terrier German Shepherd Dog Saluki American Water German Shorthaired Samoyed Spaniel Pointer Schipperke Anatolian Shepherd German Wirehaired Scottish Deerhound Dog Pointer Scottish Terrier Australian Cattle Dog Giant Schnauzer Sealyham Terrier Australian Shepherd Glen of Imaal Terrier Shetland Sheepdog Australian Terrier Golden Retriever Shiba Inu Basenji Gordon Setter Shih Tzu Basset Hound Great Dane Siberian Husky Beagle Great Pyrenees Silky Terrier Bearded Collie Greater Swiss Mountain Skye Terrier Beauceron Dog Smooth Fox Terrier Bedlington Terrier Greyhound Soft Coated Wheaten Belgian Malinois Harrier Terrier Belgian Sheepdog Havanese Spinone Italiano Belgian Tervuren Ibizan Hound Staffordshire Bull Bernese Mountain Dog Irish Setter Terrier Bichon Frise Irish Terrier Standard Schnauzer Black and Tan Irish Water Spaniel Sussex Spaniel Coonhound Irish Wolfhound Swedish Vallhund Black Russian Terrier Italian Greyhound Tibetan Mastiff Bloodhound Japanese Chin Tibetan Spaniel Border Collie Keeshond Tibetan Terrier Border Terrier Kerry Blue Terrier Toy Fox Terrier Borzoi Komondor Vizsla Boston Terrier Kuvasz Weimaraner Bouvier des -
Pharmacology of Ophthalmologically Important Drugs James L
Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.